Q4 2015 13F Holders as of 31 Dec 2015
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
27,209,685
-
Share change
-
+5,521,349
-
Total reported value
-
$929,575,673
-
Put/Call ratio
-
90%
-
Price per share
-
$34.16
-
Number of holders
-
101
-
Value change
-
+$189,567,566
-
Number of buys
-
72
-
Number of sells
-
23
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2015
As of 31 Dec 2015 Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) had 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 27,209,685 shares of stock of the company.
Largest 10 holders included Essex Woodlands Health Ventures, Inc., FRANKLIN RESOURCES INC, NQ HCIF GP, Ltd., JPMORGAN CHASE & CO, Bank of New York Mellon Corp, Polar Capital LLP, BlackRock Fund Advisors, VANGUARD GROUP INC, CANADA PENSION PLAN INVESTMENT BOARD, and LORD, ABBETT & CO. LLC.
This table shows 101 institutional shareholders of the security as of 31 Dec 2015.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.